Why did Monash IVF Group (ASX:MVF) downgrade its FY26 earnings guidance?

Monash IVF Group lowered its profit outlook due to softer-than-expected activity across the Australian Assisted Reproductive Technology market in the second half of the financial year. Recent Medicare data revealed that national stimulated cycle volumes dropped by 4.7% on a rolling three-month basis to the end of April.

What is the new FY26 profit guidance for Monash IVF Group (ASX:MVF)?

Monash IVF Group now forecasts its FY26 underlying net profit after tax (NPAT) to be between $17 million and $18 million. This revised range directly reflects the lower domestic cycle volumes experienced during the second half of the fiscal year.

How is Monash IVF Group (ASX:MVF) performing in market share despite the industry slowdown?

Despite a contracting domestic market, Monash IVF expanded its footprint by increasing its Australian stimulated cycle market share by 1.0% to a total of 20.1% on a rolling three-month basis.

What role do international operations play in the Monash IVF Group (ASX:MVF) investment thesis?

Monash IVF’s international business is acting as a growth hedge against weak domestic conditions, with second-half volumes projected to be materially higher than the prior corresponding period. This international growth helps diversify the company's revenue streams and offsets some of the macroeconomic headwinds impacting its Australian clinics.

What are the main bull and bear points for Monash IVF Group (ASX:MVF) after this news?

The bull case rests on Monash IVF growing domestic market share to 20.1%, strong international volume growth, and ongoing clinical expansion. The bear case centres on a cyclical downturn in the Australian ART market, where a 4.7% drop in industry-wide volumes highlights that IVF spending remains vulnerable to broader macroeconomic pressures.

Image for illustrative purposes only. Not a real photo.

Monash IVF lowers FY26 profit guidance

Written by Isaac FrancisPublished Jun 11, 2026, 11:59 PM

Monash IVF Group (ASX:MVF) has revised its financial outlook for the 2026 financial year, advising the market that it now forecasts an underlying net profit after tax of between $17 million and $18 million.

The primary catalyst for the downgraded earnings guidance is softer-than-anticipated activity across the Australian Assisted Reproductive Technology sector during the second half of the fiscal year.

According to recently released Medicare data, national stimulated cycle volumes contracted by 4.7% on a rolling three-month basis to the end of April compared to the prior corresponding period.

Management confirmed that these adverse macroeconomic conditions persisted throughout May and June.

Despite the broader industry slowdown, Monash IVF managed to expand its footprint, lifting its Australian stimulated cycle market share by 1% to a total of 20.1% on a rolling three-month basis.

Growth was further bolstered by the company's international operations, which are projected to deliver second-half volumes materially higher than last year.

The group continues to expand its clinical network under the guidance of newly appointed inaugural Chief Medical Officer, Fleur Cattrall, securing several key fertility specialists across Victoria and New South Wales.

While strategic cost-efficiency initiatives are well underway, CEO Victoria Atkinson noted that their financial impact on FY26 earnings remains limited due to implementation timing.

However, the measures are anticipated to yield more meaningful operational and financial contributions as the company moves into FY27.